The world’s largest pharmaceutical companies — commonly called “big pharma” — develop and commercialize the drugs and treatments that define modern medicine. Below are ten of the most widely followed big pharma stocks.
What they are known for: Currently the most valuable healthcare company in the world, driven by its absolute dominance in the booming market for GLP-1 weight-loss and diabetes medications (Mounjaro and Zepbound).
Investor Takeaway: Investors treat Eli Lilly more like a high-growth tech stock than a traditional pharma company. The primary focus is on their manufacturing capacity — how fast they can produce their obesity drugs to meet insatiable global demand — and their emerging pipeline of Alzheimer’s treatments.
What they are known for: The Danish pharmaceutical giant that pioneered the GLP-1 craze. They are essentially a pure-play powerhouse in diabetes and obesity care, famous for Ozempic and Wegovy.
Investor Takeaway: Novo Nordisk operates in a virtual duopoly with Eli Lilly in the obesity space. Investors watch them for clinical trial updates proving that their weight-loss drugs do more than just shed pounds — such as reducing cardiovascular risks and kidney disease — which forces insurance companies to cover the expensive treatments.
What they are known for: A massive, deeply entrenched healthcare behemoth. Having recently spun off its consumer products division (Band-Aids, Tylenol), J&J is now strictly focused on high-margin innovative medicines (pharma) and medical technologies (surgical robotics, implants).
Investor Takeaway: J&J is the ultimate defensive, “sleep well at night” stock. Investors hold it for its AAA-rated fortress balance sheet, its highly predictable cash flows, and a legendary track record of increasing its dividend every year for over six decades.
What they are known for: The company behind Keytruda, the world’s highest-grossing drug. Keytruda is a revolutionary immunotherapy that treats multiple types of cancer, generating tens of billions in revenue alongside Merck’s dominant vaccine business (Gardasil).
Investor Takeaway: The entire investor narrative around Merck revolves around the looming “patent cliff” in 2028 when Keytruda loses exclusivity. Investors are hyper-focused on how management is using current cash flows to buy out smaller biotechs and restock their drug pipeline for the next decade.
What they are known for: Historically famous for Humira, a blockbuster immunology drug that was the world’s best-selling medicine for years. They are also known for aggressively acquiring Allergan, giving them ownership of the highly lucrative Botox franchise.
Investor Takeaway: AbbVie is viewed as a masterclass in corporate transition. Investors watch it for its high dividend yield and are closely monitoring how well its newer blockbuster immunology drugs (Skyrizi and Rinvoq) are offsetting the revenue declines now that Humira is facing generic competition.
What they are known for: A legacy pharma giant that achieved unprecedented global scale by developing the most widely used COVID-19 vaccine and antiviral pill (Paxlovid), generating record-breaking cash windfalls during the pandemic.
Investor Takeaway: Pfizer is currently a massive turnaround story. With COVID revenues having crashed back to earth, the stock has been heavily discounted. Investors are waiting to see if Pfizer’s aggressive deployment of its pandemic cash pile into major acquisitions (like buying cancer-specialist Seagen for $43 billion) will successfully rebuild its pipeline.
What they are known for: A British-Swedish multinational with a heavy, highly successful focus on oncology, cardiovascular, and rare diseases. They also have a uniquely strong footprint in emerging markets, particularly China.
Investor Takeaway: Viewed as one of the fastest-growing mega-cap pharmas. Investors appreciate its highly productive internal R&D engine and its successful integration of Alexion Pharmaceuticals, which allowed it to dominate the incredibly lucrative, high-margin rare-disease space.
What they are known for: A massive Swiss multinational focusing purely on innovative prescription medicines, spanning cardiovascular, immunology, and targeted cancer therapies.
Investor Takeaway: Having recently spun off its generic drugs division (Sandoz), investors view Novartis as a streamlined, higher-margin, pure-play innovative pharma company. The market rewards it for its pipeline efficiency and strong track record of consistent shareholder returns.
What they are known for: One of the original biotechnology pioneers, focusing on complex, difficult-to-manufacture biologic drugs for cardiovascular disease, oncology, and bone health.
Investor Takeaway: Amgen is highly regarded for two distinct strategies: its aggressive, profitable push into “biosimilars” (complex generic versions of competitors’ biologic drugs), and massive acquisitions (like Horizon Therapeutics) to break into high-growth rare disease markets.
What they are known for: Heavy-hitting, foundational drugs in oncology (like the immunotherapy Opdivo) and cardiovascular care (like the blood thinner Eliquis).
Investor Takeaway: A classic deep-value play in the pharma sector. The stock trades at a very low multiple because several of its top-selling drugs are facing patent expirations in the coming years. Investors buying BMY are making a bet that its massive dividend yield is safe and that its recent string of acquisitions will successfully plug the upcoming revenue holes.